Immunomodulatory Properties of Antifungal Agents on Phagocytic Cells

REFERENCES

• Anderson, J. B. (2005). Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 3(7):547–556.
   PubMed Web of Science ®Google Scholar
• Antachopoulos, C., Roilides, E. (2005). Cytokines and fungal infections. Br. J. Haematol. 129(5):583–596.
   PubMed Web of Science ®Google Scholar
• Ballesta, S., Garcia, I., Perea, E. J., Pascual, A. (2005). Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 55(5):785–787.
   PubMed Web of Science ®Google Scholar
• Baltch, A. L., Bopp, L. H., Smith, R. P., Ritz, W. J., Carlyn, C. J., Michelsen, P. B. (2005). Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages. Diagn. Microbiol. Infect. Dis. 52(4):299–304.
   PubMed Web of Science ®Google Scholar
• Baltch, A. L., Bopp, L. H., Smith, R. P., Ritz, W. J., Michelsen, P. B. (2008). Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. J. Antimicrob. Chemother. 62(6):1285–1290.
   PubMed Web of Science ®Google Scholar
• Bellocchio, S., Gaziano, R., Bozza, S., Rossi, G., Montagnoli, C., Perruccio, K., Calvitti, M., Pitzurra, L., Romani, L. (2005). Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother. 55(2):214–222.
   PubMed Web of Science ®Google Scholar
• Blanco, J. L., Garcia, M. E. (2008). Immune response to fungal infections. Vet. Immunol. Immunopathol. 125(1–2):47–70.
   PubMed Web of Science ®Google Scholar
• Bopp, L. H., Baltch, A. L., Ritz, W. J., Michelsen, P. B., Smith, R. P. (2006). Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages. J. Med. Microbiol. 55(Pt 7):865–870.
   PubMed Web of Science ®Google Scholar
• Chiller, T., Farrokhshad, K., Brummer, E., Stevens, D. A. (2002). Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans. Med. Mycol. 40(1): 21–26.
   PubMed Web of Science ®Google Scholar
• Choi, J. H., Brummer, E., Stevens, D. A. (2004). Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect. 6(4):383–389.
   PubMed Web of Science ®Google Scholar
• Choi, J. H., Kwon, E. Y., Park, C. M., Choi, S. M., Lee, D. G., Yoo, J. H., Shin, W. S. and Stevens, D. A. (2010). Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia. Med. Mycol. 48(5):704–709.
   PubMed Web of Science ®Google Scholar
• Cleary, J. D., Rogers, P. D., Chapman, S. W. (2001). Differential transcription factor expression in human mononuclear cells in response to amphotericin B: identification with complementary DNA microarray technology. Pharmacotherapy 21(9):1046–1054.
   PubMed Web of Science ®Google Scholar
• Dotis, J., Simitsopoulou, M., Dalakiouridou, M., Konstantinou, T., Panteliadis, C., Walsh, T. J., Roilides, E. (2008). Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: comparison with Aspergillus fumigatus. J. Antimicrob. Chemother. 61(4):810–817.
   PubMed Web of Science ®Google Scholar
• Dotis, J., Simitsopoulou, M., Dalakiouridou, M., Konstantinou, T., Taparkou, A., Kanakoudi-Tsakalidou, F., Walsh, T. J., Roilides, E. (2006). Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus. Antimicrob. Agents Chemother. 50(3):868–873.
   PubMed Web of Science ®Google Scholar
• Ellis, M. (2000). Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections? Transpl. Infect. Dis. 2(2):51–61.
   PubMedGoogle Scholar
• Frank, U., Greiner, M., Engels, I., Daschner, F. D. (2004). Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes. Eur. J. Clin. Microbiol. Infect. Dis. 23(9):729–731.
   PubMed Web of Science ®Google Scholar
• Gallagher, J. C., MacDougall, C., Ashley, E. S., Perfect, J. R. (2004). Recent advances in antifungal pharmacotherapy for invasive fungal infections. Expert. Rev. Anti-Infect. Ther. 2(2):253–268.
   PubMedGoogle Scholar
• Gil-Lamaignere, C., Roilides, E., Maloukou, A., Georgopoulou, I., Petrikkos, G., Walsh, T. J. (2002). Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J. Antimicrob. Chemother. 50(6):1027–1030.
   PubMed Web of Science ®Google Scholar
• Graybill, J. R., Bocanegra, R., Luther, M. (1995). Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 14(8):700–703.
   PubMed Web of Science ®Google Scholar
• Graybill, J. R., Bocanegra, R., Najvar, L. K., Loebenberg, D., Luther, M. F. (1998). Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob. Agents Chemother. 42(10):2467–2473.
   PubMed Web of Science ®Google Scholar
• Hamad, M. (2008). Antifungal immunotherapy and immunomodulation: a double-hitter approach to deal with invasive fungal infections. Scand. J. Immunol. 67(6):533–543.
   PubMed Web of Science ®Google Scholar
• Herrmann, J. L., Dubois, N., Fourgeaud, M., Basset, D., Lagrange, P. H. (1994). Synergic inhibitory activity of amphotericin-B and gamma interferon against intracellular Cryptococcus neoformans in murine macrophages. J. Antimicrob. Chemother. 34(6):1051–1058.
   PubMed Web of Science ®Google Scholar
• Hiemenz, J. W., Walsh, T. J. (1996). Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22 Suppl 2:S133–144.
   PubMed Web of Science ®Google Scholar
• Hohl, T. M., Feldmesser, M., Perlin, D. S., Pamer, E. G. (2008). Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J. Infect. Dis. 198(2):176–185.
   PubMed Web of Science ®Google Scholar
• Jahn, B., Rampp, A., Dick, C., Jahn, A., Palmer, M., Bhakdi, S. (1998). Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level. Antimicrob. Agents Chemother. 42(10):2569–2575.
   PubMed Web of Science ®Google Scholar
• Janes, M. R., Fruman, D. A. (2009). Immune regulation by rapamycin: moving beyond T cells. Sci. Signal 2(67):pe25.
   PubMed Web of Science ®Google Scholar
• Kimberg, M., Brown, G. D. (2008). Dectin-1 and its role in antifungal immunity. Med. Mycol. 46(7):631–636.
   Google Scholar
• Lamaris, G. A., Lewis, R. E., Chamilos, G., May, G. S., Safdar, A., Walsh, T. J., Raad II, J., Kontoyiannis, D. P. (2008). Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J. Infect. Dis. 198(2):186–192.
   PubMed Web of Science ®Google Scholar
• Laniado-Laborin, R. and Cabrales-Vargas, M. N. (2009). Amphotericin B: side effects and toxicity. Rev. Iberoam. Micol. 26(4):223–227.
   PubMed Web of Science ®Google Scholar
• Martin, E., Stuben, A., Gorz, A., Weller, U., Bhakdi, S. (1994). Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans. Antimicrob. Agents Chemother. 38(1):13–22.
   PubMed Web of Science ®Google Scholar
• Matsuo, K., Hotokezaka, H., Ohara, N., Fujimura, Y., Yoshimura, A., Okada, Y., Hara, Y., Yoshida, N., Nakayama, K. (2006). Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules. Microbiol. Immunol. 50(4):337–347.
   PubMed Web of Science ®Google Scholar
• Mencacci, A., Cenci, E., Bacci, A., Bistoni, F., Romani, L. (2000). Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis. J. Infect. Dis. 181(2):686–694.
   PubMed Web of Science ®Google Scholar
• Morschhauser, J. (2010). Regulation of multidrug resistance in pathogenic fungi. Fungal Genet. Biol. 47(2):94–106.
   PubMed Web of Science ®Google Scholar
• Murphy, E. A., Davis, J. M., Carmichael, M. D. (2010). Immune modulating effects of beta-glucan. Curr. Opin. Clin. Nutr. Metab. Care 13(6):656–661.
   PubMed Web of Science ®Google Scholar
• Netea, M. G., Van der Meer, J. W., Kullberg, B. J. (2006). Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Clin. Microbiol. Infect. 12(5):404–409.
   PubMed Web of Science ®Google Scholar
• Pascual, A., Garcia, I., Conejo, C., Perea, E. J. (1993). Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 37(2):187–190.
   PubMed Web of Science ®Google Scholar
• Patera, A. C., Menzel, F., Jackson, C., Brieland, J. K., Halpern, J., Hare, R., Cacciapuoti, A., Loebenberg, D. (2004). Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis. Antimicrob. Agents Chemother. 48(8):3154–3158.
   PubMed Web of Science ®Google Scholar
• Razonable, R. R., Henault, M., Lee, L. N., Laethem, C., Johnston, P. A., Watson, H. L., Paya, C. V. (2005). Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob. Agents Chemother. 49(4):1617–1621.
   PubMed Web of Science ®Google Scholar
• Rodriguez, M. M., Pastor, F. J., Calvo, E., Salas, V., Sutton, D. A., Guarro, J. (2009). Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob. Agents Chemother. 53(12):5022–5025.
   PubMed Web of Science ®Google Scholar
• Rogers, P. D., Jenkins, J. K., Chapman, S. W., Ndebele, K., Chapman, B. A., Cleary, J. D. (1998). Amphotericin B activation of human genes encoding for cytokines. J. Infect. Dis. 178(6):1726–1733.
   PubMed Web of Science ®Google Scholar
• Rogers, P. D., Kramer, R. E., Chapman, S. W., Cleary, J. D. (1999). Amphotericin B-induced interleukin-1beta expression in human monocytic cells is calcium and calmodulin dependent. J. Infect. Dis. 180(4):1259–1266.
   PubMed Web of Science ®Google Scholar
• Rogers, P. D., Pearson, M. M., Cleary, J. D., Sullivan, D. C., Chapman, S. W. (2002). “Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis. J. Antimicrob. Chemother. 50(6):811–817.
   PubMed Web of Science ®Google Scholar
• Rogers, P. D., Stiles, J. K., Chapman, S. W., Cleary, J. D. (2000). Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1. J. Infect. Dis. 182(4):1280–1283.
   PubMed Web of Science ®Google Scholar
• Roilides, E., Lyman, C. A., Filioti, J., Akpogheneta, O., Sein, T., Lamaignere, C. G., Petraitiene, R., Walsh, T. J. (2002). Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob. Agents Chemother. 46(6):1974–1976.
   PubMed Web of Science ®Google Scholar
• Roilides, E., Lyman, C. A., Panagopoulou, P., Chanock, S. (2003). Immunomodulation of invasive fungal infections. Infect. Dis. Clin. North Am. 17(1):193–219.
   PubMed Web of Science ®Google Scholar
• Roilides, E., Walsh, T. (2004). Recombinant cytokines in augmentation and immunomodulation of host defenses against Candida spp. Med. Mycol. 42(1):1–13.
   PubMed Web of Science ®Google Scholar
• Romani, L. (2004). Immunity to fungal infections. Nat. Rev. Immunol. 4(1):1–23.
   PubMed Web of Science ®Google Scholar
• Safdar, A., Shelburne, S. A., Evans, S. E., Dickey, B. F. (2009). Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin. Drug Saf. 8(4):435–449.
   PubMed Web of Science ®Google Scholar
• Salvenmoser, S., Seidler, M. J., Dalpke, A., Muller, F. M. (2010). Effects of caspofungin, Candida albicans and Aspergillus fumigatus on toll-like receptor 9 of GM-CSF-stimulated PMNs. FEMS Immunol. Med. Microbiol. 60(1):74–77.
   PubMedGoogle Scholar
• Sau, K., Mambula, S. S., Latz, E., Henneke, P., Golenbock, D. T., Levitz, S. M. (2003). The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J. Biol. Chem. 278(39):37561–37568.
   PubMed Web of Science ®Google Scholar
• Saxena, S., Bhatnagar, P. K., Ghosh, P. C., Sarma, P. U. (1999). Effect of amphotericin B lipid formulation on immune response in aspergillosis. Int. J. Pharm. 188(1):19–30.
   PubMedGoogle Scholar
• Simitsopoulou, M., Gil-Lamaignere, C., Avramidis, N., Maloukou, A., Lekkas, S., Havlova, E., Kourounaki, L., Loebenberg, D., Roilides, E. (2004). Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans. Antimicrob. Agents Chemother. 48(10):3801–3805.
   PubMed Web of Science ®Google Scholar
• Simitsopoulou, M., Roilides, E., Dotis, J., Dalakiouridou, M., Dudkova, F., Andreadou, E., Walsh, T. J. (2005). Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother. 49(4):1397–1403.
   PubMed Web of Science ®Google Scholar
• Simitsopoulou, M., Roilides, E., Georgiadou, E., Paliogianni, F., Walsh, T. J. (2011). “Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus. Med. Mycol. 49(2):176–185.
   PubMed Web of Science ®Google Scholar
• Simitsopoulou, M., Roilides, E., Maloukou, A., Gil-Lamaignere, C., Walsh, T. J. (2008a). “Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses 51(2):147–154.
   PubMed Web of Science ®Google Scholar
• Simitsopoulou, M., Roilides, E., Paliogianni, F., Likartsis, C., Ioannidis, J., Kanellou, K., Walsh, T. J. (2008b). Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors. Antimicrob. Agents Chemother. 52(9):3301–3306.
   PubMed Web of Science ®Google Scholar
• Sorrell, T. C., Chen, S. C. (2009). Fungal-derived immune modulating molecules. Adv. Exp. Med. Biol. 666:108–120.
   PubMed Web of Science ®Google Scholar
• Steinbach, W. J., Stevens, D. A. (2003). Review of newer antifungal and immunomodulatory strategies for invasive Aspergillosis. Clin. Infect. Dis. 37 Suppl 3: S157–187.
   PubMedGoogle Scholar
• Stevens, D. A., Kullberg, B. J., Brummer, E., Casadevall, A., Netea, M. G., Sugar, A. M. (2000). Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med. Mycol. 38 Suppl 1:305–315.
   PubMed Web of Science ®Google Scholar
• Swenson, C. E., Perkins, W. R., Roberts, P., Ahmad, I., Stevens, R., Stevens, D. A., Janoff, A. S. (1998). In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob. Agents Chemother. 42(4):767–771.
   PubMed Web of Science ®Google Scholar
• Tohyama, M., Kawakami, K., Saito, A. (1996). Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide. Antimicrob. Agents Chemother. 40(8):1919–1923.
   PubMed Web of Science ®Google Scholar
• Turtinen, L. W., Bremer, L. A., Prall, D. N., Schwartzhoff, J., Hartsel, S. C. (2005). Distinct cytokine release profiles from human endothelial and THP-1 macrophage-like cells exposed to different amphotericin B formulations. Immunopharmacol. Immunotoxicol. 27(1):85–93.
   PubMed Web of Science ®Google Scholar
• Turtinen, L. W., Croswell, A., Obr, A. (2008). Microarray analysis of amphotericin B-treated THP-1 monocytic cells identifies unique gene expression profiles among lipid and non-lipid drug formulations. J. Chemother. 20(3):327–335.
   PubMed Web of Science ®Google Scholar
• Turtinen, L. W., Prall, D. N., Bremer, L. A., Nauss, R. E., Hartsel, S. C. (2004). Antibody array-generated profiles of cytokine release from THP-1 leukemic monocytes exposed to different amphotericin B formulations. Antimicrob. Agents Chemother. 48(2):396–403.
   PubMed Web of Science ®Google Scholar
• Vautier, S., Sousa Mda, G., Brown, G. D. (2010). C-type lectins, fungi and Th17 responses. Cytokine Growth Factor Rev. 21(6):405–412.
   PubMed Web of Science ®Google Scholar
• Villar, C. C., Dongari-Bagtzoglou, A. (2008). Immune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis. Expert Rev. Mol. Med. 10:e29.
   PubMedGoogle Scholar
• Vora, S., Chauhan, S., Brummer, E., Stevens, D. A. (1998). Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 42(9):2299–2303.
   PubMed Web of Science ®Google Scholar
• Wellington, M., Dolan, K., Krysan, D. J. (2009). Live Candida albicans suppresses production of reactive oxygen species in phagocytes. Infect. Immun. 77(1):405–413.
   PubMed Web of Science ®Google Scholar
• Wheeler, R. T., Kombe, D., Agarwala, S. D., Fink, G. R. (2008). Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog. 4(12):e1000227.
   PubMed Web of Science ®Google Scholar
• Willment, J. A., Brown, G. D. (2008). C-type lectin receptors in antifungal immunity. Trends Microbiol. 16(1):27–32.
   PubMed Web of Science ®Google Scholar
• Yamamoto, M., Takeda, K. (2010). Current views of toll-like receptor signaling pathways. Gastroenterol. Res. Pract. 2010:240–365.
   Web of Science ®Google Scholar
• Zelante, T., Bozza, S., De Luca, A., D’Angelo, C., Bonifazi, P., Moretti, S., Giovannini, G., Bistoni, F. and Romani, L. (2009). Th17 cells in the setting of Aspergillus infection and pathology. Med. Mycol. 47 Suppl 1:S162–169.
   PubMedGoogle Scholar